Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05251038
Other study ID # HCRN GI21-499
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date September 13, 2022
Est. completion date January 31, 2023

Study information

Verified date February 2023
Source Hoosier Cancer Research Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 31, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Subject must meet all of the following applicable inclusion criteria to participate in this study: - Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. - Age = 18 years at the time of consent. - ECOG Performance Status of 0-1 within 14 days prior to registration. - Histological or cytological confirmation of pancreatic cancer per AJCC, 8th edition. - Unresectable or metastatic pancreatic cancer. - Measurable disease according to RECIST 1.1 within 28 days prior to registration. - KRAS p. G12C mutation by CLIA certified molecular testing of tumor biopsy or blood based circulating tumor DNA. NOTE: patients must have KRAS p.G12C molecularly confirmed previously or have archived tissue sent for testing and/or undergo biopsy confirming KRAS p.G12C mutation prior to enrollment. - Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 28 days prior to registration: - Hematological - Absolute Neutrophil Count (ANC): = 1.5 x 109/L - Hemoglobin (Hgb): = 9 g/dL; Transfusion permitted within 1 week - Platelet Count (Plt): = 100 x 109/L - Renal - Calculated creatinine clearance1: = 50 mL/min - Creatinine (Cr): = 1.5 × upper limit of normal (ULN) - Hepatic - Bilirubin: = 1.5 × upper limit of normal (ULN) - Aspartate aminotransferase (AST) : = 2.5 × ULN; if liver metastases are present, = 5 x ULN - Alanine aminotransferase (ALT): = 2.5 × ULN; if liver metastases are present, = 5 x ULN - Coagulation ---International Normalized Ratio (INR) or Prothrombin Time (PT) or Activated Partial Thromboplastin Time (aPTT): = 1.5 × ULN; this would not apply to patient's on anti-coagulation therapy (which is permitted on study; EXCEPT Warfarin) - Progression of disease after first line chemotherapy or recurrent disease either during or < 6 months after last dose of systemic therapy administered for curative intent. - Prior cancer treatment (including investigational agents) must be completed at least 2 weeks prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia or neuropathy) to Grade = 1 or baseline. - Life expectancy > 3 months in the opinion of the investigator. - Therapeutic or palliative radiation >/= 2 weeks from registration is allowed provided subject has recovered from all reversible acute toxic effects to Grade </= 1 or baseline. - Ability to take oral medications. - Females of childbearing potential with a male partner able to father a child must have a negative pregnancy test within 7 days prior to registration. See protocol for definition of childbearing potential. - Females of childbearing potential with a male partner able to father a child and male participants able to father a child who have a female partner of childbearing potential must be willing to abstain from heterosexual intercourse or to use effective method(s) of contraception as outlined in protocol. - As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: Subjects meeting any of the criteria below may not participate in the study: - Receipt of two or more lines of chemotherapy. NOTE: Adjuvant or neoadjuvant therapy would be counted as one line of therapy if recurrence or development of metastatic disease occurred within 6 months of last dose of adjuvant/neoadjuvant therapy. - Previous treatment with a KRASG12C inhibitor. - Patient unable to receive nal-IRI/5FU/LV or GEM/nab-paclitaxel as second line chemotherapy for pancreatic cancer. - Grade 2 or higher neuropathy preventing treatment with abraxane containing regimen. - History of pneumonitis and/or interstitial lung disease (ILD). - Active brain metastases and/or carcinomatous meningitis from non-brain tumors. NOTE: Subjects who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study Day 1 are eligible if they meet all of the following criteria: a) residual neurological symptoms grade = 2; b) on stable doses of dexamethasone, if applicable; and c) follow-up magnetic resonance imaging (MRI) performed within 28 days shows no new lesions appearing. - Active infection requiring antibiotics within 1 week of enrollment. - Cardiac dysfunction: - Myocardial Infarction within 6 months of enrollment - NYHA > class II CHF - unstable angina - arrhythmia requiring medication - QTc > 470msec. - Has a known history of Hepatitis B or C. NOTE: Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. NOTE: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority. - Has a known history of Human Immunodeficiency Virus (HIV) infection. NOTE: Subjects with HIV/AIDS with adequate antiviral therapy to control viral load would be allowed if they are stable and have been on treatment for = 4 weeks prior to first dose of study drug(s). Subjects with viral hepatitis with controlled viral load would be allowed while on suppressive antiviral therapy. Testing not required.no testing for HIV is required unless mandated by local health authority. - Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen, per treating physician discretion, are not eligible for this trial. - History or presence of hematological malignancies unless curatively treated with no evidence of disease = 2 years. - Surgery within 28 days of enrollment. - Known dihydropyrimidine dehydrogenase deficiency. - Use of known CYP3A4 and P-gp sensitive substrates (with a narrow therapeutic window), within 14 days or 5 half-lives of the drug or its major active metabolite, whichever is longer, prior to study Day 1 that was not reviewed and approved by the principal investigator. - Use of strong inducers of CYP3A4 (including herbal supplements such as St. John's wort) within 14 days or 5 half-lives (whichever is longer) prior to study day 1 that was not reviewed and approved by the principal investigator. - Female subjects who are breastfeeding or who plan to breastfeed while on study and through the timeframe as described in protocol (NOTE: breast milk cannot be stored for future use while the mother is being treated on study). Male participants who plan to donate sperm while on study and through the timeframe as described in protocol. - Use of warfarin. NOTE: use of low molecular weight heparin (LMWH) are permitted. - Acid reducing agents including proton pump inhibitors (PPIs) and H2 receptor antagonists. Alternative agents to acid reducing agents are permitted. If an acid-reducing agent cannot be avoided, administer sotorasib 4 hours before or 10 hours after acid-reducing agent use.

Study Design


Intervention

Drug:
Sotorasib
Intervention instruction outlined in protocol
Liposomal Irinotecan (nal-IRI)
Intervention instruction outlined in protocol
5 Fluorouracil (5FU)
Per standard of care
Leucovorin (LV)
Per standard of care
Gemcitabine (GEM)
Per standard of care
Nab paclitaxel
Per standard of care

Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Devalingam Mahalingam Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) Clinical activity will be assessed by overall response rate (ORR). ORR is defined as the percentage of patients whose best response is Complete Response (CR) plus those with Partial Response (PR) based on RECIST 1.1. 2 years
Secondary Assess Adverse Events Characterize the safety and tolerability of patients receiving sotorasib combined with chemotherapy for second line treatment of pancreas cancer. Determine safety and tolerability as determined by NCI CTCAE v 5.0 2 months
Secondary Progression Free Survival (PFS) Determine progression free survival (PFS) including the 6- month, 1- year, 2-year and median progression free survival. PFS is defined from the date from first dose of study drug administration (C1D1) until the date of first documentation of progressive disease by RECIST 1.1 or death from any cause, whichever comes first 6 months, 1 year, and 2 years
Secondary Duration of Response (DoR) Determine the Duration of Response (DOR). DOR is defined from the date of first documentation of response to treatment, to the date of first documentation of progressive disease by RECIST 1.1 or death, whichever comes first, in patients who experience a response. 2 years
Secondary Disease Control Rate (DCR) Determine the Disease Control Rate (DCR). DCR is defined as the percentage of patients whose best response is complete response (CR) plus partial response (PR) plus stable disease (SD) by RECIST 1.1. 2 years
Secondary Overall Survival (OS) Determine Overall Survival (OS). OS is assessed from the date of registration to the study until the date of death from any cause for up to 2 years. 2 years
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study